PVLA — Palvella Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $990.95m
- $943.40m
- 35
- 18
- 85
- 42
Annual income statement for Palvella Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 29.3 | 31.4 | 25.9 | 42.8 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 63.2 | 79.6 | 61.2 | 72.6 | 14.1 |
| Operating Profit | -33.9 | -48.1 | -35.3 | -29.8 | -14.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -37.1 | -45.7 | -33.3 | -24.5 | -17.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -37.2 | -45.7 | -33.3 | -24.5 | -17.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -37.2 | -45.7 | -33.3 | -24.5 | -17.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -37.2 | -45.7 | -33.3 | -24.5 | -17.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -54.7 | -61.3 | -44.7 | -2.76 | -7.83 |